Verve Therapeutics, Inc. - VERV STOCK NEWS

Verve Therapeutics announces updated preclinical data on its base editing therapies targeting ANGPTL3 and PCSK9 genes for treating atherosclerotic cardiovascular disease (ASCVD). Data demonstrated durable and well-tolerated gene editing in non-human primates, with significant reductions in blood ANGPTL3 and PCSK9 proteins. The findings support the potential of these therapies to offer long-term LDL-C lowering solutions, particularly for patients with unmet needs. The data is being presented at the American College of Cardiology 71st Annual Scientific Session on April 4, 2022.

Verve Therapeutics, a biotechnology company focused on cardiovascular disease treatment, has announced that its Chief Scientific Officer, Dr. Andrew Bellinger, will participate in a fireside chat at the Guggenheim Genomic Medicines and Rare Disease Conference on March 31, 2022, at 10:00 a.m. ET. The event will be available via a live webcast on the company's investor website and archived for 60 days. Verve is known for its innovative gene editing medicines, including its lead product candidate, VERVE-101, aimed at permanently reducing LDL cholesterol levels to mitigate cardiovascular disease risk.

Verve Therapeutics reported significant progress toward its clinical initiatives and pipeline advancements in its Q4 and 2021 financial results. The company has substantial cash reserves of $360.4 million, ensuring runway into 2024. They aim to initiate the clinical trial for VERVE-101 targeting heterozygous familial hypercholesterolemia (HeFH) and commence IND-enabling studies for their ANGPTL3 program in the second half of 2022. Despite a net loss of $31.3 million in Q4 2021, Verve's ongoing innovation positions it favorably in addressing cardiovascular diseases.

Verve Therapeutics, a biotechnology firm focused on innovative cardiovascular treatments, will have its CEO, Sekar Kathiresan, present at the Cowen 42nd Annual Healthcare Conference on March 8, 2022, at 9:10 a.m. ET. The presentation will be available via live webcast on the company’s investor website, archived for 60 days afterward. Verve specializes in gene editing medicines, targeting genes like PCSK9 and ANGPTL3 to lower LDL cholesterol levels, aiming to transform cardiovascular disease care. Their lead candidate, VERVE-101, is in IND-enabling studies, particularly aimed at treating familial hypercholesterolemia.

Verve Therapeutics (VERV) made significant strides in early 2022, announcing key milestones for its cardiovascular gene editing programs. The lead program, VERVE-101, targets the PCSK9 gene to lower LDL-C levels, with regulatory submissions and the first patient treatment expected in the second half of 2022. Preclinical data in non-human primates show promising results, indicating the potential for re-dosing and sequential dosing of therapies. The company is positioned to transition to a clinical-stage organization, aiming for transformative advancements in the treatment of atherosclerotic cardiovascular disease.

Verve Therapeutics, a biotech innovator focused on cardiovascular disease, announced that CEO Sekar Kathiresan will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 4:30 p.m. ET. The company is pioneering gene editing medicines to transform cardiovascular care, including its lead product candidate VERVE-101, which aims to permanently disable the PCSK9 gene to lower LDL-C levels, particularly for patients with familial hypercholesterolemia. A live webcast will be available on their website and archived for 60 days.

Verve Therapeutics (Nasdaq: VERV) has appointed Allison Dorval as the new Chief Financial Officer. With over 20 years of experience in finance and investor relations from companies like Voyager Therapeutics, her leadership is expected to guide Verve through its next crucial milestones. The firm is advancing its gene editing therapies targeting cardiovascular disease, particularly with the upcoming launch of clinical trials for VERVE-101. This strategic addition comes post-IPO, aimed at bolstering corporate growth and addressing regulatory engagements in 2022.

Verve Therapeutics (Nasdaq: VERV) reported promising preclinical data for its gene editing therapies at TIDES 2021, demonstrating significant PCSK9 protein and LDL-C reductions. The company plans to initiate clinical development of VERVE-101 in 2022, targeting heterozygous familial hypercholesterolemia. Its ANGPTL3 program also showed effective liver-targeted delivery with the proprietary GalNAc-LNP technology. As of September 30, 2021, Verve's cash position stood at $389.2 million, with R&D expenses rising to $17.5 million, reflecting increased investment in future clinical trials.

Verve Therapeutics has announced new preclinical data showcasing its GalNAc-LNP technology for the delivery of an ANGPTL3 base editor in non-human primates (NHPs) with homozygous familial hypercholesterolemia (HoFH). The study demonstrated a 94-97% reduction in blood ANGPTL3 protein levels, along with a nearly 35% decrease in low-density lipoprotein cholesterol (LDL-C). These findings support the potential for broad applicability of this gene editing approach in cardiovascular disease treatments. The company aims to further advance its ANGPTL3 program and initiate investigational new drug-enabling studies in 2022.